Navigation Links
Entry inhibitors show promise as drugs with new MOA for treatment of HBV and HDV infection
Date:4/2/2011

Berlin, Germany, Saturday 02 April 2011: Promising new viral hepatitis data presented today at the International Liver CongressTM show that entry inhibitors --a new mechanism of action for drugs to treat viral hepatitis -- could provide the first new hepatitis B and hepatitis D treatments for many years.1,2

Most current approved therapies directly target viral replication (e.g. nucleotide/side analogues), and can lead to the development of viral resistance or viral rebound after the end of treatment. Entry inhibitors prevent the virus from entering the cell and forming a stable replication complex, limiting the issue of viral rebound and resistance development.

Professor Heiner Wedemeyer, EASL's Secretary General, commented: "The current treatments available for hepatitis B & D are limited. These novel drugs are the first promising treatments for many years. The shift in the mechanism of action of these drugs from inhibiting the virus's replication directly to inhibiting its entry into the cell, and thus its replication means they are less likely to produce viral resistance; a huge problem faced by many of today's clinicians."

One study1 showed that treatment of ex-vivo liver cells with synthetic anti-lipopolysaccharide peptides (SALPs) during and prior to HBV infection was highly effective and dose dependent in inhibiting infection reducing markers of HBV infection (e.g. HBV RNA, HBV antigens) in the concentration range of 4-5 g/mL by 90% and 0.5-2 g/mL by 50%.

The study also demonstrated that SALPs showed activity against other viral (e.g. HIV, herpes) and microbial (e.g. peritonitis, colitis and pneumonia) infections. Therefore, SALPs represent a very promising therapeutic strategy to treat viral hepatitis infection and concomitant bacterial infection which often leads to life threatening systematic complications.

Other studies2,3 illustrated the enormous value of the chimaeric mouse model of chronic HBV and
'/>"/>

Contact: Travis Taylor
easlpressoffice@cohnwolfe.com
44-784-306-9451
European Association for the Study of the Liver
Source:Eurekalert

Page: 1 2

Related biology news :

1. No-entry zones for AIDS virus
2. New growth inhibitors more effective in plants, less toxic to people
3. A powerful new technology to identify HIV inhibitors
4. KINAXO launches KinAffinity services for efficient profiling of kinase inhibitors in cells or tissue
5. Will loss of plant diversity compromise Earths life-support systems?
6. New test shows promise for accurate diagnosis of Turner syndrome
7. Stem cells show promise in repairing a childs heart
8. Scripps Research team creates new synthetic compound with HIV-fighting promise
9. RevaTen platelet-rich plasma shows promise as potential treatment for heart attacks
10. Co-management holds promise of sustainable fisheries worldwide
11. New method for making tiny catalysts holds promise for air quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... meeting painted a stark warning on the possible effects ... greenhouse effect 32 times that of carbon dioxide. Now ... substances act as fully regenerable electron acceptors which helps ... wetlands instead of being released to the atmosphere. However, ... it may enter into a vicious cycle to release ...
(Date:4/17/2014)... Medical Branch at Galveston are the first to ... cervical cancer should begin colorectal cancer screening earlier ... finding a high incidence of secondary colorectal cancers ... new recommendations that the younger women in this ... after their initial cervical cancer diagnosis instead of ...
(Date:4/17/2014)... View of Domestication," a special feature of The ... ( PNAS ) published April 29, raises a ... deep history that most of us take for granted. ... in many spots around the globe shifted from hunting ... and plants. , It seems so straightforward and yet ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
... one of the most important prerequisites for a positive self ... rather than the exception that children and young people are ... or subject to bullying are particularly critical of their appearance ... long period. This is revealed in a new thesis in ...
... Prevention (CDC) today released new infection control recommendations ... (KPC)-Producing Organisms, one of the most ... that infections with these highly resistant bacteria are ... In Guidance for Control of Infections with Carbapenem-Resistant ...
... the media. A new study by Dr. Yaniv Levyatan ... of Israel,s National Security College, describes how our side ... "Information warfare" plays a crucial role in ... conventional weapons. Therefore, the information warfare against terrorist organizations ...
Cached Biology News:Children who are dissatisfied with their appearance often have problems with their peer group 2Press statement on new CDC MMWR on Klebseilla pneumonia Carbapenemase-producing organisms 2Information warfare in the 21st century: Ideas are sometimes stronger than bombs 2
(Date:1/15/2014)... the device," Nobel laureate Herbert Kroemer famously observed, ... at the junctures where layers of different materials ... interfaces between layers of metal oxides are becoming ... as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing ...
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... January 15, 2014 More than 5 ... about 1 in 3 seniors will die with Alzheimer’s ... These jaw-dropping figures have shocked many Americans into looking ... help prevent these tragic age-related cognitive disorders. Jonathan Weisman, ...
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
Breaking Biology Technology:A deeper look at interfaces 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... July 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") ... highlights for the three and six month ... experienced a strong second quarter with the ... therapy treatment in,refractory head and neck cancer ...
... DIEGO, July 29 Arena Pharmaceuticals,Inc. (Nasdaq: ... quarter 2008,financial results after the NASDAQ Global Market ... Jack Lief, Arena,s President and Chief,Executive Officer, and ... Financial Officer, will host a conference call at ...
... Abt Associates has been,ranked 19th in the Marketing News ... Research firms. The listing is based on 2007 revenue ... for,calendar 2007 was $55.1 million. Total company revenues for ... Abt Associates market research activities are carried out ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 2Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 3Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 4Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 5Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 6Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 7Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 8Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 9Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 10Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 11Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 12Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 13Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 14Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 15Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 16Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 17Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 18Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 19Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 20Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 21Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 22Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 23Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 24Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 25Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 26Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 27Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 28Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 29Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 30Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 31Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 32Oncolytics Biotech Inc. Announces 2008 Second Quarter Results 33Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008 2Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008 3Abt Associates Ranked One of Top 20 U.S. Market Research Firms 2
Kanamycin is used for selection of resistant bacteria. C18H36N4O11xH2SO4. Contains 10 mg/ml kanamycin (base) utilizing kanamycin sulfate in 0.85% saline....
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
...
...
Biology Products: